FDA Drug Shortage Database
Hydromorphone (Dilaudid) shortage
The FDA Drug Shortage Database lists 12 of 27 hydromorphone presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on October 31, 2017. 14 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule II
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 0.25mg/0.5ml injection | 1 | 0 | 0 |
| 0.5mg/0.5ml injection | 1 | 0 | 0 |
| 1mg/1ml injection | 4 | 1 | 0 |
| 2mg/1ml injection | 5 | 3 | 0 |
| 3mg | 0 | 0 | 1 |
| 4mg/1ml injection | 0 | 2 | 0 |
| 10mg/1ml injection | 1 | 6 | 0 |
| 50mg/5ml injection | 0 | 1 | 0 |
| 500mg/50ml injection | 0 | 1 | 0 |
Which presentations are listed?
Limited or unavailable now (12)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11) | Fresenius Kabi USA, LLC | Current posted November 1, 2017, updated September 15, 2026 | Unavailable; Other |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Unavailable; Other |
| Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11) | Fresenius Kabi USA, LLC | Current posted November 1, 2017, updated October 6, 2026 | Unavailable; Other |
| Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01) | Hospira, Inc., a Pfizer Company | Current posted November 1, 2017, updated September 22, 2026 | Unavailable; Other |
| Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01) | Hospira, Inc., a Pfizer Company | Current posted November 1, 2017, updated September 22, 2026 | Limited Availability; Other |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Unavailable; Other |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03) | Teva Pharmaceuticals USA, Inc. | Current posted November 1, 2017, updated October 1, 2026 | Limited Availability; Other |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Limited Availability; Other |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01) | Hikma Pharmaceuticals USA, Inc. | Current posted November 1, 2017, updated September 18, 2026 | Unavailable; Demand increase for the drug |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
Listed now, available (14)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01) | Teva Pharmaceuticals USA, Inc. | Current posted November 1, 2017, updated October 1, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03) | Teva Pharmaceuticals USA, Inc. | Current posted November 1, 2017, updated October 1, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10) | Fresenius Kabi USA, LLC | Current posted November 1, 2017, updated October 6, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
Resolved or discontinued (1)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06) | Padagis US LLC | To Be Discontinued posted July 23, 2026, updated July 23, 2026 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Acetaminophen and hydrocodone | Pain | No current entry | 36 labelers | $0.152 per tablet 10-325 mg tablet |
| Oxycodone | Pain | No current entry | 32 labelers | $0.0884 per tablet 5 mg tablet |
| Acetaminophen and oxycodone | Pain | A presentation being discontinued | 29 labelers | $0.183 per tablet 7.5-325 mg tablet |
| Tramadol | Pain | No current entry | 39 labelers | $0.0248 per tablet 50 mg tablet |
| Morphine | Pain | In shortage | 22 labelers | $0.226 per tablet 15 mg tablet |
| Acetaminophen and codeine | Pain | No current entry | 24 labelers | $0.256 per tablet 3 tablet |
| Methadone | Pain | No current entry | 18 labelers | $0.177 per tablet 10 mg tablet |
| Oxymorphone | Pain | No current entry | 9 labelers | n/a |
| Tapentadol | Pain | No current entry | 4 labelers | $14.48 per tablet 100 mg tablet |
| Hydrocodone | Pain | No current entry | 1 labeler | $7.95 per capsule 15 mg capsule |
| Acetaminophen and tramadol | Pain | No current entry | 11 labelers | $0.116 per tablet 37.5-325 mg tablet |
| Levorphanol | Pain | No current entry | 7 labelers | $10.65 per tablet 2 mg tablet |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage